Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 206-735-5 | CAS number: 371-40-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Neurotoxicity
Administrative data
Description of key information
The clinical signs and the neurohistopathological changes indicate neurotoxicity of the test item.
Key value for chemical safety assessment
Effect on neurotoxicity: via oral route
Link to relevant study records
- Endpoint:
- neurotoxicity: acute oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Peer reviewed literature. Neither guideline nor GLP compliant study only basic information is available.
- Principles of method if other than guideline:
- Well reported study with basic information
- GLP compliance:
- not specified
- Limit test:
- yes
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 4 weeks old
- Housing: Polycarbonate cages (three rats per cage)
- Diet: MF, Oriental Yeast Co., Ltd, Tokyo, Japan ad libitum
- Water: Sterilized water ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24 °C
- Humidity (%): 40-70%
- Photoperiod: 12-h light/dark cycle. - Route of administration:
- oral: gavage
- Analytical verification of doses or concentrations:
- not specified
- Frequency of treatment:
- Once
- Remarks:
- Doses / Concentrations:
600 mg/kg bw
Basis:
nominal conc. - No. of animals per sex per dose:
- 9 (males)
- Control animals:
- yes, concurrent vehicle
- Observations and clinical examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: 30 min and 5 h after dosing and once a day thereafter for the following 15 days
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: all rats 2 days before dosing and on day 9, and on all the surviving rats on day 15
BODY WEIGHT: Yes
- Time schedule for examinations: Before dosing and on days 2, 4, 8, 15 and 16 - Sacrifice and (histo)pathology:
- - Time point of sacrifice: On day 10 and the other rats were killed on day 16
- Number of animals sacrificed: Three rats from each experimental group
- Procedures for perfusion: Phosphate buffer solution
- Tissues evaluated: Forebrain, including cerebral cortex, basal ganglia and corpus callosum; midbrain, including hippocampus, thalamus and hypothalamus; mesencephalon, including substantia nigria, colliculi, tectum and tegmentum; hindbrain, including cerebellum, pons and medulla oblongata; spinal cords, including cervical, thoracic and lumbar levels; trigeminal nerves with gasserian ganglia; and sciatic nerves. - Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Neuropathological findings:
- effects observed, treatment-related
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Cyanosis between days 1 and 4
NEUROBEHAVIOUR
Reduced response to extensor thrust of the hindlimb was found on days 9 and 15. Gait abnormalities, including ataxia or hindlimb paralysis
A significant decrease in grip strength of the hindlimbs was found in the on day 9 compared with the corresponding control group.
Abnormal landing, such as on the animal’s side in the aerial righting reflex, was found on day 9.
NEUROPATHOLOGY
Neuronal cells were not damaged in any rats of the treated groups. No histopathological abnormalities in the nervous tissues were found in any rats in the control group.
Histopathological findings:
- A spongy change in the white matter of the spinal cords was found
- The lesions arose symmetrically and they were prominent in the lateral and ventral funiculi of the white matter. The lesions in the thoracic level were most prominent throughout the spinal cord. A spongy change in the tegmentum of the mesencephalon or the spinocellebelar tracts of the pons and medulla oblongata, and nerve fibre degeneration in the spinal nerves, trigeminal nerves, or sciatic nerves were also found.
Conclusion:
Previous study demonstrated that a bolus dose of aniline to rats induces neurotoxicity characterized by hindlimb paralysis on clinical observation and spongy change in the white matter of the spinal cord on histopathological examination. The results of the present study indicate that 4-halogenated anilines also cause neurotoxicity in rats.
The clinical signs (including hindlimb paralysis) and the neurohistopathological changes (including the spongy change in the white matter of the spinal cord) were of the same character as those induced by aniline intoxication.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Quality of whole database:
- Peer reviewed literature. Neither guideline nor GLP compliant study only basic information is available.
Effect on neurotoxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Effect on neurotoxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Supporting study
In the published report at Okazaki et al. (2003) the potential for neurotoxicity after a single oral dose of four halogenated aniline derivatives was given to rats was investigated at or near the lethal dosage level of 600 mg/kg bw.
Hindlimb paralysis was found in the test item group on clinical observation, with the maximum incidence of 100% in the test item group.
Detailed clinical observations with functional tests identified the following effects: reduced response of hindlimb extensor thrust, gait abnormality in the open field and decreased grip strength in the foreor hindlimbs, abnormal landing in the aerial righting reflex. Spongy change in the white matter of the spinal cord and brainstem and nerve fibre degeneration in the peripheral nerves were found in all haloaniline-treated groups.
This study demonstrates that a bolus dose of 4-haloanilines to rats induces neurotoxicity similar in character to that evoked by the parent aniline.
Justification for selection of effect on neurotoxicity via oral route endpoint:
Peer reviewed literature. Neither guideline nor GLP compliant study only basic information is available.
Justification for classification or non-classification
Dangerous Substance Directive
(67/548/EEC)
The available study is considered reliable and suitable for
classification purposes under Directive 67/548/EEC. As a result
the substance is considered not to be classified for neurotoxicity under
Directive 67/548/EEC, as amended for the 31st time in Directive
2009/2/EG.
Classification, Labelling, and Packaging
Regulation (EC) No 1272/2008
The available experimental test data are reliable and suitable for
classification purposes under Regulation (EC) No 1272/2008. As a result
the substance is considered not to be classified for neurotoxicity under
Regulation (EC) No 1272/2008, as amended for the sixth time in
Regulation (EC) No 605/2014.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.